Exploration of the Mitochondria as a Potential Therapeutic Target in Duchenne Muscular Dystrophy

Simple item page
dc.contributor.advisorChristopher G. R. Perry
dc.contributor.authorCatherine Anne Bellissimo
dc.date.accessioned2024-07-18T21:15:27Z
dc.date.available2024-07-18T21:15:27Z
dc.date.copyright2023-04-11
dc.date.issued2024-07-18
dc.date.updated2024-07-18T21:15:26Z
dc.degree.disciplineKinesiology & Health Science
dc.degree.levelDoctoral
dc.degree.namePhD - Doctor of Philosophy
dc.description.abstractDuchenne muscular dystrophy (DMD) is a fatal muscle wasting condition resulting from the loss of the structural protein dystrophin. The disease is characterized by severe muscle wasting and weakness that results in early death due to cardiac and/or respiratory failure. Currently, there is no cure for DMD and current standard of care (glucocorticoid steroids) only addresses secondary pathologies, and is accompanied with a myriad of negative side effects. Previous work has established the mitochondria as a contributor to dystrophic pathology and a valid therapeutic target. The primary focus of this thesis was to examine novel therapies that modulate metabolism in DMD, to determine if secondary pathologies, including fibrosis, atrophy, weakness and mitochondrial stress are attenuated. Additionally, we aimed consider the effects of adenylates and creatine metabolism on mitochondrial permeability transition (mtPT) in a permeabilized muscle fibre system. Our study findings reveal that ATP significantly attenuates mtPT and that both creatine and ADP should be considered in buffer composition for assessment of mtPT. Next, using the mitochondrial-enhancing compound, Olesoxime, we examined the effect of attenuating mitochondrial stress on dystrophic pathology. Unexpectedly, improvements to mitochondrial respiration and reactive oxygen species attenuation, were creatine-dependent, indicating that creatine sensitivity was preserved by Olesoxime treatment. These improvements to bioenergetics also happened in association with markers of muscle breakdown (serum creatine kinase), and improvement in muscle function (cage hand time and recovery of diaphragm force after fatigue). Finally, short-term treatment with the novel adiponectin receptor agonist, ALY688-SR, mitigated aspects of mitochondrial stress in quadriceps, diaphragm and hippocampus, while improving markers of fibrosis and muscle atrophy in the diaphragm, and recognition memory. Overall, this thesis indicates that attenuating mitochondrial stress in dystrophic muscle and brain improves markers of muscle function and quality, while preserving cognitive function and warrants longer term treatment protocols.
dc.identifier.urihttps://hdl.handle.net/10315/42111
dc.languageen
dc.rightsAuthor owns copyright, except where explicitly noted. Please contact the author directly with licensing requests.
dc.subjectKinesiology
dc.subjectPhysiology
dc.subject.keywordsskeletal muscle
dc.subject.keywordsmitochondria
dc.subject.keywordsDuchenne muscular dystrophy
dc.subject.keywordsbioenergetics
dc.subject.keywordsatrophy
dc.subject.keywordsweakness
dc.titleExploration of the Mitochondria as a Potential Therapeutic Target in Duchenne Muscular Dystrophy
dc.typeElectronic Thesis or Dissertation

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Bellissimo_Catherine_A_2023_Phd.pdf
Size:
9.45 MB
Format:
Adobe Portable Document Format
Download

Collections

ETD SWORD Deposit

All items in the YorkSpace institutional repository are protected by copyright, with all rights reserved except where explicitly noted.